Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$211.17 USD

211.17
2,255,897

-16.27 (-7.15%)

Updated Jul 26, 2024 04:00 PM ET

After-Market: $210.00 -1.17 (-0.55%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Biogen (BIIB) Board Okays Hemophilia Business Spin-off

Biogen (BIIB) announced that its board of directors has approved the spin-off of its hemophilia business into a new company Bioverativ Inc.

    Biogen Names Commercial Officer as New CEO, Shares Fall

    Biogen Inc. (BIIB) has appointed its present chief commercial officer (CCO), Michel Vounatsos, as the new chief executive officer (CEO), effective Jan 6, 2017.

      The Zacks Analyst Blog Highlights: Barclays, Netflix, NIKE, Biogen and China Petroleum & ChemicalThe Zacks Analyst Blog Highlights: Barclays, Netflix, NIKE, Biogen and China Petroleum & Chemical

      The Zacks Analyst Blog Highlights: Barclays, Netflix, NIKE, Biogen and China Petroleum & Chemical

        Arpita Dutt headshot

        Biotech Stock Roundup: Ophthotech Slumps on Fovista Results, Achaogen Skyrockets on Data

        Several companies presented data this week with companies like Achaogen (AKAO) soaring while others like Ophthotech plunged.

          Mark Vickery headshot

          Top Research Reports for Barclays, Netflix and Nike

          Today's Research Daily features new research reports on 16 major stocks, including Barclays (BCS), Netflix (NFLX) and NIKE (NKE).

            Biogen Presents Positive Early Data from Alzheimer's Study

            Last week, Biogen Inc. (BIIB) presented positive data from a phase I study (PRIME) on its anti-amyloid treatments in development, aducanumab, at the Clinical Trials on Alzheimer's Disease (CTAD) meeting in San Diego.

              Lilly/AstraZeneca Expand Alzheimer Disease Collaboration

              Eli Lilly and Company (LLY) and AstraZeneca plc (AZN) expanded their existing collaboration to develop the second treatment for Alzheimer's disease, MEDI1814

                Stock Market News for December 08, 2016

                The Trump induced rally continued to boost major benchmarks to finish at all-time record highs on Wednesday offsetting the decline in healthcare stocks.

                  GW Pharmaceuticals (GWPH): What Awaits in Q4 Earnings?

                  GW Pharmaceuticals (GWPH) is set to report fourth-quarter fiscal 2016 results on Dec 5. The company posted positive surprise of 57.80% in the last quarter.

                    Arpita Dutt headshot

                    Biotech Stock Roundup: Actelion Soars on Acquisition Talks, Another Clinical Hold for Juno

                    With Johnson & Johnson eyeing Actelion (ALIOF), will mergers and acquisitions pick pace in the biotech sector?

                      The Zacks Analyst Blog Highlights: Biogen, Honda, Intel, CSX and General Growth Properties

                      The Zacks Analyst Blog Highlights: Biogen, Honda, Intel, CSX and General Growth Properties

                        Sheraz Mian headshot

                        Top Research Reports for Intel, Honda & Biogen

                        Today's Research Daily features new research reports on 16 major stocks, including Biogen (BIIB), Honda (HMC) and Intel (INTC).

                          Company News for November 08, 2016

                          Companies in the News are: BRK.B,LC,BID,BIIB,IONS

                            Zacks Industry Outlook Highlights: Bristol-Myers, Biogen, Merck, Celgene and ARIAD Pharmaceuticals

                            Zacks Industry Outlook Highlights: Bristol-Myers, Biogen, Merck, Celgene and ARIAD Pharmaceuticals

                              Arpita Dutt headshot

                              Fundamentals Remain Strong in the Pharma Sector

                              We could see several M&A agreements being announced in the coming quarters, though companies are wary of bidding wars leading to over-priced deals.

                                Stock Market News for October 12, 2016

                                Disappointing start to the third quarter earnings season weighed on benchmarks on Tuesday

                                  6 Healthcare Stocks Investors Cannot Miss in Q3 Earnings

                                  A number of healthcare companies are recording improvements in their financial numbers.

                                    Stock Market News for September 21, 2016

                                    Benchmarks finished slightly higher on Tuesday ahead of the two-day policy meetings of the Fed and Bank of Japan (BOJ) ending today

                                      Sheraz Mian headshot

                                      Top 3 Research Reports for August 15, 2016

                                      Today's must-read reports are for AstraZeneca (AZN), Caterpillar (CAT) and Exelon (EXC).

                                        Sheraz Mian headshot

                                        Fresh Research Reports For Intel (INTC), AT&T (T) & Others

                                        Today's must-read reports are for Intel (INTC), Biogen (BIIB) and AT&T (T).

                                          Arpita Dutt headshot

                                          Pharma Industry Outlook: Fundamentals Remain Strong

                                          It's been a rough start to the year for pharma and biotech with several factors weighing on the sector.

                                            Stock Market News for July 07, 2016

                                            Benchmarks ended in the green on Wednesday after the FOMC minutes from June meeting showed that most of the Fed policymakers were in favor of keeping rates unchanged.

                                              Stock Market News for June 16, 2016

                                              Benchmarks ended in the red for the fifth consecutive session on Wednesday after the Fed opted to keep interest rate unchanged and raised concerns about number of hikes this year

                                                Stock Market News for May 10, 2016

                                                Benchmarks closed mixed on Monday after gains in healthcare stocks offset declines in energy stocks

                                                  Arpita Dutt headshot

                                                  Pharma Industry Stock Outlook - March 2016

                                                  Looking at consensus earnings expectations, the Medical sector, which had performed well in 2015, is expected to see earnings growth of 0.7% and revenue growth of 7.7% in Q1.